Leonardo Brunetti

🫁 Can Local Ablative Therapy Add More Power To First-Line EGFR TKI Treatment? A new systematic review and meta-analysis in the Journal of Thoracic Oncology evaluated the integration of local ablative therapy (LAT) with EGFR TKIs in advanced EGFR-mutated NSCLC. The signal was clinically meaningful: 🔹 31 studies included 🔹 3,355 patients analyzed 🔹 PFS improved with LAT + EGFR TKI: HR 0.45 🔹 OS also favored LAT + EGFR TKI: HR 0.52 🔹 Benefit was seen with both upfront and consolidative LAT strategies 🔹 Pneumonitis was more frequent, but grade ≥3 toxicities were uncommon As first-line EGFR+ NSCLC treatment becomes more complex, LAT may offer a different kind of intensification, focused, multidisciplinary, and potentially less systemically toxic. The next question is not only whether LAT works, but which patients benefit most, when it should be delivered, and how it fits into the modern osimertinib era. oncodaily.com/oncolibrary/lu… @Brunet3Leon @GiuliaLaCavaMD @valentsant @pecci_federica1 @JuliaRotow @AminNassarMD @adib_elio @thenasheffect @M_Tagliamento @RobertoFerrara_ @FCitarellaMD @BRicciutiMD @finn_corinne @HendriksLizza @APassaroMD @dplanchard @PassigliaFra @ACortelliniMD #LungCancer #NSCLC #EGFR #EGFRMutatedNSCLC #ThoracicOncology #RadiationOncology #SBRT #PrecisionOncology #OncoDaily

First-line #EGFR+ #NSCLC is rapidly evolving with more effective systemic strategies. But is there a “third way” of intensification? In our meta-analysis just published in @JTOonline, integrating LAT with EGFR TKIs significantly improved PFS and OS with acceptable safety. ➡️ Upfront integration in 1L may be where LAT expresses its full potential. Grateful to all co-authors and especially @Brunet3Leon for leading this effort. @dplanchard @BRicciutiMD @JuliaRotow @APassaroMD @thenasheffect @AminNassarMD @adib_elio @GiuliaLaCavaMD @valentsant @RobertoFerrara_ @HendriksLizza @finn_corinne @FabianAckerMD @derosa__lisa @IASLC @PoliclinCampus @CampusBioMedico @ImperialSandC 🔗 jto.org/article/S1556-…

Integrating LAT With EGFR TKIs Improves Outcomes in EGFR+ NSCLC - Alessio Cortellini @ACortelliniMD @JTOonline @Brunet3Leon @dplanchard @BRicciutiMD @JuliaRotow @APassaroMD @thenasheffect @AminNassarMD @adib_elio @GiuliaLaCavaMD @valentsant @RobertoFerrara_ @HendriksLizza @finn_corinne @FabianAckerMD @derosa__lisa oncodaily.com/voices/alessio… #OncoDaily #Oncology #Cancer #Health #Medicine #LungCancer #MedX #MedTwitter #NSCLC

First-line #EGFR+ #NSCLC is rapidly evolving with more effective systemic strategies. But is there a “third way” of intensification? In our meta-analysis just published in @JTOonline, integrating LAT with EGFR TKIs significantly improved PFS and OS with acceptable safety. ➡️ Upfront integration in 1L may be where LAT expresses its full potential. Grateful to all co-authors and especially @Brunet3Leon for leading this effort. @dplanchard @BRicciutiMD @JuliaRotow @APassaroMD @thenasheffect @AminNassarMD @adib_elio @GiuliaLaCavaMD @valentsant @RobertoFerrara_ @HendriksLizza @finn_corinne @FabianAckerMD @derosa__lisa @IASLC @PoliclinCampus @CampusBioMedico @ImperialSandC 🔗 jto.org/article/S1556-…

At #TTLC26, Ross Camidge delivered a powerful reflection on his personal journey with lung cancer, offering insight into how it has influenced his work and life. Read the full recap in ILCN: bit.ly/4lw4ywi

Reconstructing individual patient survival data (IPD) for scientific re-use has never been as easy as it is with V-Exploder (v-exploder.com). Happy to announce that the video tutorial is out: youtu.be/X1PSf62ew1U?si… 🚀

The most inspiring and beautiful talk I had the luck of attending! An immense thank you @DRCamidge #NSCLC #LungCancer

Not to say I told you so at #ASCO25.... we should all remember not to fall too in love with our own ideas, or we risk undermining them. It’s a shame, because this also puts the credibility of everyone working in this field at risk. I’m sure there are plenty of honest, motivated researchers who truly believe in what they do. Hopefully the authors will be able to respond adequately, but in general it’s better to be cautious with any claim. Thanks to @houndcl for running the numbers for us. @IASLC @AIOMtweet

On the occasion of World Cancer Day 2026, #FGB, with the support of the Prada Group and in collaboration with @ESOncology, announces the 3 winners of the fifth edition of the Fellowship named after Gianni Bonadonna. Press Release fondazionebonadonna.org/wp-content/upl…) #PradaGroup #Esoncology

Very proud of our own @Brunet3Leon who has been awarded the Gianni Bonadonna Fellowship @ESOncology to spend a year at @DanaFarber Thanks to @BRicciutiMD for the support and for welcoming him to the team. fondazionebonadonna.org/premiati-tre-g…

After years of work in this space, we try to bring some order to a complex field.. New review in Current Oncology Reports-@SpringerNature on host related determinants of ICI response in NSCLC: body composition, metabolism, sex, and systemic inflammation👇 @valentsant @Brunet3Leon @DJPinato @pecci_federica1 @BRicciutiMD @IASLC link.springer.com/article/10.100…

Out on @LungCaJournal 👇 Despite overall poor prognosis, 13% of pts with #NSCLC and PS≥2 reached 5-year OS with IO mono (PD-L1 high setting) Out of ~40 variables, none alone explains it while AI reveals a complex, dynamic prognosis driven by more than disease-related factors only. Thanks to all the co-authors and collaborators! @IASLC @CampusBioMedico @ImperialSandC lungcancerjournal.info/article/S0169-…

🎥@valentsant of @DanaFarber shares findings on how PD-L1 tumor proportion score (TPS) predicts survival differently across #NSCLC subtypes: ⭐TPS shows stepwise benefit in non-squamous disease, but acts as a dichotomous marker in squamous histology Watch➡️ow.ly/1QNc50X9Hm0 @IASLC #WCLC25 #LCSM #LungCancer #ImmunoOnc This video is available on the Lung Cancer Channel on VJOncology, an independent medical education platform, which is supported by Johnson & Johnson and Takeda. Supporters have no influence over the production of content.

📢Out now in @jitcancer! Global Pembro-5Y registry (61 centers, 14 countries) + advanced stats & AI 👇 1) In modern day oncology (1/4 patients alive at 5y) Prognosis is dynamic, not static 2) AI reveals time-dependent complexity 3) Comorbidities regain importance over time jitc.bmj.com/content/13/9/e…

Closing out #WCLC25 with gratitude for physician–scientist @DiFedericoMD and our fellows @EdoardoGarbo, @valentsant, #EleonoraGariazzo I’m lucky to work with, who presented studies to help move us closer to more personalized treatments for patients with lung cancer. 👏🌍#IMG

Couldn't be prouder of @Brunet3Leon and @valentsant presenting their work at #wclc2025! Two great residents from @CampusBioMedico now boosting their research skills and career path abroad with 2 great mentors and friends @BRicciutiMD and @DJPinato ❤️😍🇮🇹

Best Poster Prize for “Hepatocellular and Non-Biliary Liver Cancer” at @myESMO #ESMOGI25 🏆Awarded to @paslombardi 👉Clinical refractoriness to AtezoBev in HCC Congratulations, very well defended piece of work 👏🏻👏🏻 #ESMOAmbassadors

The best team I could ever dream of! Two of the best posters in this photo (at my sides) 🙄 #ESMOGI @myESMO @DJPinato @paslombardi @imperialcollege

Cancer research DOES make a difference! #NSCLC evidence.nejm.org/doi/full/10.10…

Happy to share our latest work - the result of a collective effort by our Italian Lung Cancer Network group in Lazio! A concrete example of regional collaboration in clinical research! @valentsant mdpi.com/3379680 #mdpicancers via @Cancers_MDPI @MDPIOpenAccess